How consistently do physicians diagnose and manage drug-induced interstitial lung disease? Two surveys of European ILD specialist physicians
Year: 2020
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Currently there are no general guidelines for diagnosis or management of suspected drug-induced (DI) interstitial lung disease (ILD). The objective was to survey a sample of current European practice in the diagnosis and management of DI-ILD, in the context of the prescribing information approved by regulatory authorities for 28 licenced drugs with a recognised risk of DI-ILD. METHODS: a website link. Initially, opinion was sought regarding various diagnostic and management options based on seven clinical ILD case vignettes and five general questions regarding DI-ILD. The second survey involved 29 statements regarding the diagnosis and management of DI-ILD, derived from the results of the first survey. Consensus agreement was defined as 75% or greater. RESULTS: When making a diagnosis of DI-ILD, the favoured investigations used (other than computed tomography) included pulmonary function tests, bronchoscopy and blood tests. The preferred method used to decide when to stop treatment was a pulmonary function test. In the second survey, the majority of the statements were accepted by the 33 respondents, with only four of 29 statements not achieving consensus when the responses "agree" and "strongly agree" were combined as one answer. CONCLUSION: The two surveys provide guidance for clinicians regarding an approach to the diagnosis and management of DI-ILD in which the current evidence base is severely lacking, as demonstrated by the limited information provided by the manufacturers of the drugs associated with a high risk of DI-ILD that we reviewed.
Source: ERJ Open Research
Institutions: Sheffield Teaching Hospitals NHS Foundation Trust, University of Sheffield, Royal National Hospital for Rheumatic Diseases, Manchester Academic Health Science Centre, Royal United Hospital, University of Manchester, Royal United Hospital Bath NHS Trust, Arthritis Research UK, Manchester University NHS Foundation Trust, Wythenshawe Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $808
Funders: Aarhus Universitet, Aarhus Universitetshospital, University of Bern, Royal Devon and Exeter NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust, Nottingham University Hospitals NHS Trust, Royal Brompton and Harefield NHS Foundation Trust, University Hospitals of Leicester NHS Trust, Heart of England NHS Foundation Trust, European Federation of Pharmaceutical Industries and Associations, University Hospitals Birmingham NHS Foundation Trust, University College London, University of Oxford, European Commission, University of Nottingham, Universität Heidelberg, Ege Üniversitesi, Newcastle upon Tyne Hospitals NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, University College London Hospitals NHS Foundation Trust, Université de Lyon
OpenAlex ID: W3010657367